Rockefeller Capital Management
SLN icon

Rockefeller Capital Management’s Silence Therapeutics SLN Stock Holding History

Rockefeller Capital Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$492 Hold
45
– – ﹤0.01% 4730
2026
Q2 		$494 Hold
45
– – ﹤0.01% 4601
2026
Q1 		$237 Hold
45
– – ﹤0.01% 4596
2025
Q4 		$274 Hold
45
– – ﹤0.01% 4574
2025
Q3 		$234 Buy
+45
New +$250 ﹤0.01% 4340

Other funds holding SLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Rockefeller Capital Management's SLN Position: Q3 2026 in Review

Rockefeller Capital Management held its Silence Therapeutics (SLN) position steady in Q3 2026 at 45 shares worth $492. The position accounts for ﹤0.01% of the portfolio, ranked #4730.

Rockefeller Capital Management first reported a position in SLN in Q3 2025 and has held it in 5 quarters since. The position peaked at $494 in Q2 2026. 43 funds tracked by Wall St. Rank hold SLN as of Q3 2026.

  • Rockefeller Capital Management held 45 shares of Silence Therapeutics worth $492 as of Q3 2026.
  • Rockefeller Capital Management left its Silence Therapeutics share count unchanged in Q3 2026.
  • Silence Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4730 holding.
  • Rockefeller Capital Management first reported a position in Silence Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Rockefeller Capital Management's Silence Therapeutics position peaked at $494 in Q2 2026.
  • 43 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.